These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 15517872

  • 1. Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
    Kawamoto T, Akisue T, Marui T, Nakatani T, Hitora T, Fujita I, Kurosaka M, Yamamoto T.
    Anticancer Res; 2004; 24(5A):2675-9. PubMed ID: 15517872
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 3. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
    Yoshitani K, Honoki K, Morishita T, Kido A, Miyauchi Y, Mii Y, Takakura Y.
    In Vivo; 2003; 17(3):255-8. PubMed ID: 12929576
    [Abstract] [Full Text] [Related]

  • 4. Expression of stem cell factor and c-kit in human malignant fibrous histiocytoma cell line (TNMY1).
    Nakatani T, Marui T, Yamamoto T, Hitora T, Akisue T, Kawamoto T, Nagira K, Fujita I, Matsumoto K, Yoshiya S, Kurosaka M.
    Anticancer Res; 2003; 23(3B):2329-33. PubMed ID: 12894511
    [Abstract] [Full Text] [Related]

  • 5. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB.
    J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
    [Abstract] [Full Text] [Related]

  • 6. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines.
    Mayorga ME, Sanchis D, Perez de Santos AM, Velasco A, Dolcet X, Casanova JM, Baradad M, Egido R, Pallares J, Espurz N, Benitez D, Mila J, Malvehy J, Castel T, Comella JX, Matias-Guiu X, Vilella R, Marti RM.
    Melanoma Res; 2006 Apr; 16(2):127-35. PubMed ID: 16567968
    [Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 8. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
    Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M.
    Clin Cancer Res; 2001 Dec 01; 7(12):3884-93. PubMed ID: 11751479
    [Abstract] [Full Text] [Related]

  • 9. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R.
    Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155
    [Abstract] [Full Text] [Related]

  • 10. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T, Mareel M, Mester J, Gespach C.
    Cancer Res; 2002 Sep 01; 62(17):4879-83. PubMed ID: 12208734
    [Abstract] [Full Text] [Related]

  • 11. [In vitro killing effects of STI571 on esophageal carcinoma cell lines CE-48T and CE-81T].
    Zhang PY, Li BJ, Su XD, Wen ZS, Zhao JM, Zhang LJ, Long H, Rong TH.
    Ai Zheng; 2006 Apr 01; 25(4):456-60. PubMed ID: 16613680
    [Abstract] [Full Text] [Related]

  • 12. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
    Brama M, Basciani S, Cherubini S, Mariani S, Migliaccio S, Arizzi M, Rosano G, Spera G, Gnessi L.
    Endocr Relat Cancer; 2007 Mar 01; 14(1):61-72. PubMed ID: 17395975
    [Abstract] [Full Text] [Related]

  • 13. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
    Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET.
    Clin Cancer Res; 2003 Apr 01; 9(4):1469-73. PubMed ID: 12684421
    [Abstract] [Full Text] [Related]

  • 14. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 15. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A.
    Carcinogenesis; 2006 Mar 01; 27(3):664-71. PubMed ID: 16357008
    [Abstract] [Full Text] [Related]

  • 16. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
    Zhang P, Gao WY, Turner S, Ducatman BS.
    Mol Cancer; 2003 Jan 03; 2():1. PubMed ID: 12537587
    [Abstract] [Full Text] [Related]

  • 17. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G.
    Int J Mol Med; 2004 Sep 03; 14(3):373-82. PubMed ID: 15289888
    [Abstract] [Full Text] [Related]

  • 18. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM, Liu JC.
    J Cell Physiol; 2009 Mar 03; 218(3):568-74. PubMed ID: 19006173
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

  • 20. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B, Tirnitz-Parker JE, Olynyk JK.
    Gastroenterology; 2008 Sep 01; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.